Pipeline phases
Apr 25, 2017
Samsung biosim nod sets; Lilly’s med hits; BioMarin sees pricing; Spinraza scores; Klick creates
Samsung biosim nod sets J&J's Remicade up for tough fight Samsung Bioepis won FDA approval late Friday for its Remicade substitute, Renflexis (infliximab-abda), becoming the the second biosimilar to threaten that brand in the U.S. Not an unexpected event, and the launch isn’t expected until October because of bi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
